

Change in the Composition of the Intrasense Board of Directors

Montpellier, France, May 23, 2025, 6:00pm. Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), [the French expert in AI-enhanced medical imaging solutions that facilitate and secure diagnosis, decision-making and therapeutic follow-up](#) (the “**Company**”), announces a change in the composition of its Board of Directors

At its meeting on May 21, 2025, the Board of Directors of Intrasense noted the resignation of Mrs. Michèle Lesieur from her position as Director of the Company, effective May 23, 2025, and has co-opted Mr. Steven F. Tolle as a Director, effective May 23, 2025. Mr Steven F. Tolle has been co-opted for the remainder of Mrs. Michèle Lesieur's term of office, i.e. until the General Meeting of shareholders called in 2029 to approve the financial statements for the year ending December 31, 2028, and this co-optation will be submitted for ratification by the Company's General Meeting of shareholders to be held on June 25, 2025.

The Board of Directors warmly thanks Mrs. Michèle Lesieur for her valuable and dedicated contribution and extends a warm welcome to Mr. Steven F. Tolle. The Board looks forward to this future collaboration.



Steven F. Tolle brings over 30 years of experience in the healthcare sector, spanning medical technologies, artificial intelligence, medical devices, and digital health services.

He currently serves as Chief Product & Technology Officer at IgniteData. He was formerly General Partner at HLM Venture Partners, a venture capital fund specializing in healthcare. At IBM Watson Health, he led global strategic development for medical imaging, including a major partnership with Guerbet. He also held executive positions at Merge Healthcare, where he led a turnaround strategy prior to its acquisition by IBM for \$1 billion.

Mr. Tolle advised Guerbet's strategic committee on AI and technology trends between 2020 and 2023. His professional background includes experience in both the United States and Europe. Mr. Tolle graduated from Washington University in St. Louis.

Following this change, the Intrasense Board of Directors now consists of six members:

- [François Nicolas](#), Chairman of the Board
- [Charlotte Bamière](#), Director
- [Jérôme Estampes](#), Director
- [Anne Larpin](#), Independent Director
- [Patrice Rullier](#), Independent Director
- [Steven F. Tolle](#), Independent Director

About Intrasense

A French expert in medical imaging since 2004 and a digital subsidiary of the Guerbet Group, Intrasense designs medical imaging software solutions natively enriched by artificial intelligence algorithms.

Myrian®, an advanced radiology visualization platform featuring cutting-edge clinical tools, optimizes and simplifies the interpretation of all types of images. DUOnco™, a range of expert AI algorithms for oncology, offers an AI for the detection of focal liver lesions and the first AI dedicated to CE-marked bone lesions. Liflow®, a dedicated oncology monitoring solution integrating multi-organ AIs, optimizes the longitudinal monitoring of cancer patients.

By combining clinical expertise and operational performance, Intrasense provides healthcare professionals with high medical value tools, facilitating analysis, diagnosis and patient management. **More information on www.intrasense.fr**

Contacts

INTRASENSE

Communication officer

Salomé Sylvestre

Phone : +33 4 67 13 01 30

investisseurs@intrasense.fr

SEITOSEI.ACTIFIN

Analyst & Investor Relations

Foucauld Charavay

Phone : +33 6 37 83 33 19

intrasense@seitosei-actifin.com

Press Relations

Isabelle Dray

Phone : +33 1 56 88 11 29

isabelle.dray@seitosei-actifin.com